Programmable Bio · Hyderabad, India

Your model designed it.
Our autonomous lab tests it.

We operate a compact, fully autonomous R&D lab in Hyderabad. It is running now. We are opening selected programs to academic and industry teams while raising capital to expand its instruments, assays, and throughput.

Status: operational R&D cell
Location: Hyderabad, India
Next: scale capacity and access

Operational today. The Hyderabad lab executes automated wet-lab workflows end to end. Customer access begins through a reviewed expression of interest; a self-serve catalog and API follow as each assay is standardized.

Biology is becoming programmable

Models can now generate proteins, sequences, constructs, and experimental plans faster than laboratories can test them. The scarce resource is no longer a plausible design. It is trustworthy physical evidence.

Programmable biology needs an execution layer: software translates intent into lab operations, automation runs the experiment, and structured results flow back into the model. Our Hyderabad lab is the first compact implementation of that loop.

Design → execute → measure → learn. The product is not a robot or a report. It is a repeatable experimental loop.

From computational design to experimental evidence

Design
Your candidates
Review
Feasibility + quote
Execute
Hyderabad lab
Return
Data + provenance
Learn
Next design cycle

Initial programs are reviewed with our team so we only accept work the current cell can execute reliably. Standardized workflows will move into transparent, self-serve ordering as the public catalog expands.

See the operating model and launch catalog →

Start with a working cell. Scale into a network.

Automation already running

The core execution loop is operational in our Hyderabad R&D setup. Funding expands breadth and throughput rather than financing a first demonstration.

Price parity as a baseline

Our launch targets match published cloud-lab prices. The India cost base is intended to preserve margin while keeping experiments accessible.

Model-ready output

Each standardized assay is designed to return structured results, raw files, QC context, and execution provenance.

Clinical context is proposed

We are pursuing, but have not signed, an Apollo partnership for consented clinical and biobank access. It is an expansion path, not a current asset.

One lab, two access models

Academic R&D

Small, grant-sized experimental batches for teams whose computational output is growing faster than their bench capacity.

Industry R&D

Pilot programs now, followed by reserved capacity and API-driven design–build–test–learn loops as the fleet scales.